P546: Minimal risk of lymphoma despite long term use of azathioprine in patients with Inflammatory Bowel Disease: a longitudinal cohort analysis from Northern India.ECCO'22Year: 2022
Authors: Ranjan, M.K.(1);Kante, B.(1);Vuyyuru, S.K.(1);Kumar, P.(1);Mundhra, S.K.(1);Golla, R.(1);Sharma, R.(2);Das, P.(3);Sahni, P.(4);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
(1)All India Institute of Medical Sciences, Department of Gastroenterology and Human Nutrition, New Delhi, India;(2)All India Institute of Medical Sciences, Department of Radio Diagnosis, New Delhi, India;(3)All India Institute of Medical Sciences, Department of Pathology, New Delhi, India;(4)All India Institute of Medical Sciences, Department of Gastrointestinal Surgery, New Delhi, India;
P547: Early modification of inflammatory burden through treatment with vedolizumab or adalimumab is predictive of long-term treatment success in patients with Ulcerative Colitis from the VARSITY StudyECCO'22Year: 2022
Authors: Schreiber , S.(1);Galinsky , K.(2);Aubrecht , J.(2);Juarez , J.(2);Agboton , C.(3);Loftus Jr , E.V.(4);Danese , S.(5);
(1)University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(2)Takeda, Gastroenterology Drug Discovery Unit, Cambridge MA, United States;(3)Takeda Pharmaceuticals International, Global Medical Affairs, Zurich, Switzerland;(4)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester MN, United States;(5)IRCCS Ospedale and University Vita-Salute San Raffaele, Department of Gastroenterology, Milan, Italy;
P548: External validation and consistency in time of patient segmentation based on disease acceptance and perceived control in Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: Van Erp, L.W.(1);Thomas, P.W.A.(2);Groenen, M.J.M.(1);Bloem, S.(3);Russel, M.G.V.M.(4);Römkens, T.E.H.(5);Wahab, P.J.(1);
(1)Rijnstate Hospital, Crohn & Colitis Centre- Department of Gastroenterology and Hepatology, Arnhem, The Netherlands;(2)Radboud University Medical Centre, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(3)Nyenrode Business University, Center for Marketing & Supply Chain Management, Breukelen, The Netherlands;(4)Medical Spectrum Twente, Department of Gastroenterology and Hepatology, Enschede, The Netherlands;(5)Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, 's-Hertogenbosch, The Netherlands;
P549: Oxidative stress and antioxidant capacity biomarkers in adults and children with IBD: current update from OxIBDiet trialECCO'22Year: 2022
Authors: Quattrini, S.(1);Gatti, S.(1);Palpacelli, A.(1);Mattioli, S.(1);Cianfruglia, L.(2);Galezzi, T.(1);Monachesi, C.(1);Quatraccioni, C.(3);Catassi, G.(4);Di Sario, A.(5);Armeni, T.(2);Catassi, C.(1);
(1)Polytechnic University of Marche, Department of Pediatrics, Ancona, Italy;(2)Polytechnic University of Marche, Department of Clinical Sciences, Ancona, Italy;(3)Polytechnic University of Marche, Department of Gastroenterology, Ancona, Italy;(4)Sapienza - University of Rome, Department of Pediatrics, Rome, Italy;(5)Area vasta n.2 - Senigallia, Department of Gastroenterology, Senigallia, Italy;
P550: Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCUECCO'22Year: 2022
Authors: Chaparro, M.(1); G Donday, M.(1);Rubio, S.(2);Nuñez, A.(3);Calviño Suarez, C.(4);Madero, L.(5);Figueira, M.(6);Rivero, M.(7);Pérez Martínez, I.(8);Diz-Lois Palomares, M.T.(9);Huguet, J.M.(10);Marín Pedrosa, S.(11);Aguas, M.(12);Arroyo, M.(13);Ruiz-Cerulla, A.(14);Vázquez Morón, J.M.(15);Fernández-Clotet, A.(16);Guerra, I.(17);López Serrano, P.(18);Rodríguez-Lago, I.(19);Arias García, L.(20);Camargo Camero, R.(21);Casanova, M.J.(1);Martínez Montiel, P.(22);Sendra Rumbeu, P.(23);Suarez Ferrer, C.(24);Valldosera Gomis, G.(25);Armesto, R.(26);Bujanda, L.(27);Calvo Moya, M.(28);Hervías Cruz, D.(29);Robles Alonso, V.(30);de Jorge Turrión, M.Á.(31);Zúñiga de Mora-Figueroa, B.(32);Molina Arriero, G.(33);Acosta, D.(34);Brenes, Y.(34);Hermida, S.(34);Parra, P.(34);Gisbert, J.P.(1);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Madrid, Spain;(2)Hospital Universitario de Navarra, Gastroenterology Unit, Pamplona, Spain;(3)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(4)Complexo Hospitalario Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(5)Hospital General Universitario de Alicante, Gastroenterology Unit, Alicante, Spain;(6)Xerencia Xestión Integrada de Vigo- SERGAS. Grupo de Investigación de Patología Digestiva. Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur. SERGAS UVIGO, Gastroenterology Unit, Vigo, Spain;(7)Hospital Universitario Marqués de Valdecilla e IDIVAL, Gastroenterology Unit, Santander, Spain;(8)Hospital Universitario Central de Asturias e Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(9)Complexo Hospitalario Universitario de A Coruña, Gastroenterology Unit, A Coruña, Spain;(10)Hospital General Universitario de Valencia, Gastroenterology Unit, Valencia, Spain;(11)Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain;(12)Hospital Universitario y Politécnico La Fe and CIBEREHD, Gastroenterology Unit, Valencia, Spain;(13)Hospital Clínico Universitario Lozano Blesa and Fundación del Instituto de Investigación Sanitaria de Aragón IIS Aragón and CIBEREHD, Gastroenterology Unit, Zaragoza, Spain;(14)Hospital Universitario de Bellvitge, Gastroenterology Unit, Barcelona, Spain;(15)Hospital Universitario Juan Ramón Jimenez, Gastroenterology Unit, Huelva, Spain;(16)Hospital Universitario Clìnic i Provincial, Gastroenterology Unit, Barcelona, Spain;(17)Hospital Universitario de Fuenlabrada e Instituto de Investigación Hospital Universitario La Paz IdiPAZ, Gastroenterology Unit, Madrid, Spain;(18)Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Madrid, Spain;(19)Hospital Universitario de Galdakao- Instituto de Investigación Sanitaria Biocruces Bizkaia, Gastroenterology Unit, Galdakao, Spain;(20)Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain;(21)Hospital Universitario Virgen de La Victoria, Gastroenterology Unit, Málaga, Spain;(22)Hospital Universitario 12 de Octubre, Gastroenterology Unit, Madrid, Spain;(23)Hospital Universitario Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain;(24)Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain;(25)Hospital Universitario Joan XXIII, Gastroenterology Unit, Tarragona, Spain;(26)Complexo Hospitalario Universitario de Ourense, Gastroenterology Unit, Ourense, Spain;(27)Instituto Biodonostia- Universidad del País Vasco UPV/EHU and CIBEREHD, Gastroenterology Unit, Guipúzcoa, Spain;(28)Hospital Universitario Puerta de Hierro, Gastroenterology Unit, Majadahonda, Spain;(29)Hospital General Universitario de Cuidad Real, Gastroenterology Unit, Cuidad Real, Spain;(30)Hospital Vall d´Hebrón, Gastroenterology Unit, Barcelona, Spain;(31)Hospital Universitario de Cabueñes, Gastroenterology Unit, Gijón, Spain;(32)Hospital Clínico Universitario San Cecilio, Gastroenterology Unit, Granada, Spain;(33)Complejo Hospitalario Universitario de Ferrol, Gastroenterology Unit, A Coruña, Spain;(34)Hospital Universitario de La Princesa- IIS-IP and CIBEREHD, Clinical and Translational Research Unit. Inflammatory Bowel Disease Unit, Madrid, Spain;on behalf of DUMBO study group of GETECCU
P552: Higher Serum Ustekinumab Levels Correlate With Higher Rates Of Steroid-Free Deep Remission And Endoscopic Healing In Patients With Inflammatory Bowel DiseasesECCO'22Year: 2022
Authors: Yarur, A.(1);Ungaro, R.(2);Jain, A.(3);Nunex, L.(1);Spencer, E.(2);Bruss, A.(1);Berens, B.(1);Beniwal-Patel, P.(1);Dervieux, T.(3);Dubinsky, M.(2);
(1)Medical College of Wisconsin, Department of Gastroenterology, Milwaukee, United States;(2)The Mount Sinai Hospital, Medicine, New York, United States;(3)Prometheus Labs, Research & Developement, San Diego, United States;
P554: Vedolizumab Associated quality of Life and inflammatory bowel disease control Upon Entering a subcutaneous switching program (VALUE) – Results from a multi-centre UK studyECCO'22Year: 2022
Authors: Lim, S.(1);Gros Alcade, B.(2);Lehmann, A.(3);Lindsay, J.(3);Gaya, D.(4);Caulfield, L.(4);Dhar, A.(5);Ritchie, S.(5);Limdi, J.(6);Taylor, J.(6);Raine, T.(7);Balendran, K.(7);Shuttleworth, E.(8);Kwok, J.(8);Cococcia, S.(9);Murray, C.(9);Walker, G.(10);Aldridge, R.(10);George, B.(10);Colbert, R.(4);Dawson, P.(1);Jameson, E.(1);Irving, P.(1);Sharma, E.(1);Lees, C.(2);Samaa, M.(1);
(1)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(2)Western General Hospital, Gastroenterology, Edinburgh, United Kingdom;(3)Royal London Hospital, Gastroenterology, London, United Kingdom;(4)NHS Greater Glasgow and Clyde, Gastroenterology, Glasgow, United Kingdom;(5)County Durham and Darlingtoin NHS Foundation Trust, Gastroenterology, Durham, United Kingdom;(6)Pennine Acute Trust, Gastroenterology, Manchester, United Kingdom;(7)Cambridge University Hospitals, Gastroenterology, Cambridge, United Kingdom;(8)Lancashire Teaching Hospital, Gastroenterology, Preston, United Kingdom;(9)Royal Free Hospital, Gastroenterology, London, United Kingdom;(10)Torbay Hospital, Gastroenterology, Torquay, United Kingdom;
P555: Ustekinumab tissue and serum levels in patients with Crohn’s disease are closely correlated though not consistently associated with objective response after induction.ECCO'22Year: 2022
Authors: Proietti, E.(1,2);Bayoumy, A.(1);Pauwels, R.(1);van der Woude, J.(1);Doukas, M.(3);Oudijk, L.(3);Peppelenbosch, M.(1);Grohmann, U.(2);Crombag, R.(4);de Vries, A.(1);Fuhler, G.(1);
(1)Erasmus Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(2)University of Perugia, Department of Medicine and Surgery, Perugia, Italy;(3)Erasmus Medical Center, Department of Pathology, Rotterdam, The Netherlands;(4)Erasmus Medical Center, Department of Hospital Pharmacy, Rotterdam, The Netherlands;
P556: The effect of multiple doses of upadacitinib 45 mg on the pharmacokinetics of cytochrome P450 substrates in healthy adult subjectsECCO'22Year: 2022
Authors: Ibrahim, M.(1);Pangan, A.(2);Feng, T.(3);Mohamed, M.E.(1);
(1)AbbVie, Clinical Pharmacology and Pharmacometrics, North Chicago, United States;(2)AbbVie, Clinical Development, North Chicago, United States;(3)AbbVie, Data and Statistical Sciences, North Chicago, United States;
P558: Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study.ECCO'22Year: 2022
Authors: Cottron, C.(1);Treton, X.(2);Altwegg, R.(3);Reenaers, C.(4);Amiot, A.(5);Fumery, M.(6);Vuitton, L.(7);Peyrin-Biroulet, L.(8);Bouguen, G.(9);Dewit, O.(10);Nancey, S.(11);Caillo, L.(12);Roblin, X.(13);Beylot-Barry, M.(14);Rivière, P.(1);Laharie, D.(1);
(1)Haut-Leveque Hospital- CHU de Bordeaux, Gastroenterology, Bordeaux, France;(2)Hôpital Beaujon, gastroenterology, Clichy, France;(3)CHU Montpellier- Saint Eloi Hospital, Gastroenterology, Montpellier, France;(4)CHU Liège, Gastroenterology, Liège, Belgium;(5)Henri Mondor Hospital- APHP- Créteil, Gastroenterology, Créteil, France;(6)CHU de Amiens- and Peritox- UMR I-01, Gastroenterology, Amiens, France;(7)CHRU Besançon, Gastroenterology, Besançon, France;(8)Nancy University Hospital, Gastroenterology, Vandoeuvre les Nancy, France;(9)CHU Rennes- Univ Rennes- INSERM- CIC1414- Institut NUMECAN Nutrition Metabolism and Cancer-, Gastroenterology, Rennes, France;(10)Université Catholique de Louvain Saint Luc, Gastroenterology, Brussels, France;(11)CHU de Lyon- Lyon Sud Hospital- University Claude Bernard Lyon 1, Gastroenterology, Lyon, France;(12)CHU de Nîmes, Gastroenterology, Nîmes, France;(13)CHU de Saint-Etienne- Hôpital Nord- Université Jean Monnet- Saint-Etienne- France., Gastroenterology, Saint-Etienne, France;(14)CHU Bordeaux- hôpital Saint-André, Department of Dermatology and Pediatric Dermatology-, Bordeaux, France;
P559: Cannabis Improves Sleep Quality in Patients with Inflammatory Bowel Diseases in a Prospective Observational StudyECCO'22Year: 2022
Authors: Hirsch, A.(1);Seidenberg, C.(2);Fliss Isakov, N.(1);Meiri, D.(3);Maharshak, N.(1);
(1)Tel Aviv Medical Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel;(2)Hebrew University of Jerusalem, Department of Pharmacology, Jerusalem, Israel;(3)Technion - Israel Institute of Technology, The Laboratory of Cancer Biology and Cannabinoid Research, Haifa, Israel;
P560: Application of a clinical decision support tool for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicenter studyECCO'22Year: 2022
Authors: Kim, K.(1);Hong, S.W.(1);Park, J.H.(1);Hwang, S.W.(1,2);Park, S.H.(1,2);Yang, D.H.(1);Byeon, J.S.(1);Myung, S.J.(1);Yang, S.K.(1,2);Yoo, J.H.(3);Boo, S.J.(4);Kim, E.S.(5);Lee, J.(6);Kim, K.O.(7);Ye, B.D.(1,2);
(1)University of Ulsan College of Medicine- Asan Medical Center, Department of Gastroenterology, Seoul, Korea- Republic Of;(2)University of Ulsan College of Medicine- Asan Medical Center, Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of;(3)CHA Bundang Medical Center- CHA University School of Medicine, Department of Internal Medicine, Seongnam, Korea- Republic Of;(4)Jeju National University School of Medicine, Department of Internal Medicine, Jeju, Korea- Republic Of;(5)Korea University Anam Hospital, Department of Gastroenterology, Seoul, Korea- Republic Of;(6)Chosun University College of Medicine, Department of Internal Medicine, Gwangju, Korea- Republic Of;(7)Yeungnam University College of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;
P561: Clinical utility of therapeutic drug monitoring of adalimumab using a point of care testECCO'22Year: 2022
Authors: Stevens, T.(1);Teichert, C.(1);Volkers, A.(1);Mostafavi Montazeri, N.(1);Bahur, B.(2);Bray, K.(3);D'Haens, G.(1);
(1)Amsterdam UMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)ProciseDx Inc., Clinical Operations, San Diego, United States;(3)ProciseDx Inc., Clinical Development and Medical Affairs, San Diego, United States;
P562: A Phase 1 Study Evaluating the Effect of Coadministration of Etrasimod on the Pharmacokinetics and Pharmacodynamics of a Monophasic Oral Contraceptive in Healthy Female VolunteersECCO'22Year: 2022
Authors: Lee, C.(1);Tang , Y.(1);Villa-Caballero, L.(2);Liu , K.(3);Randle , A.(4);Grundy , J.(1);
(1)Arena Pharmaceuticals- Inc., Nonclinical Dev & Clinical Pharmacology, San Diego, United States;(2)Arena Pharmaceuticals- Inc., Clinical Development, San Diego, United States;(3)Arena Pharmaceuticals- Inc., Biostatistics & Data Mgmt, San Diego, United States;(4)Arena Pharmaceuticals- Inc., Clinical Operations, San Diego, United States;
P563: Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programmeECCO'22Year: 2022
Authors: Rubin, D.T.(1);Torres, J.(2);Regueiro, M.(3);Reinisch, W.(4);Prideaux, L.(5);Kotze, P.G.(6);Tan, F.H.(7);Gardiner, S.(8);Mundayat, R.(8);Cadatal, M.J.(9);Ng, S.(10);
(1)-, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago- IL, United States;(2)Hospital Beatriz Ângelo, Gastroenterology Division, Loures, Portugal;(3)Cleveland Clinic, Department of Gastroenterology- Hepatology and Nutrition, Cleveland- OH, United States;(4)Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria;(5)Monash Medical Centre, Department of Gastroenterology and Hepatology, Melbourne- VIC, Australia;(6)Catholic University of Paraná, IBD Outpatient Clinics- Colorectal Surgery Unit, Curitiba, Brazil;(7)-, Pfizer Australia, Melbourne- VIC, Australia;(8)-, Pfizer Inc, New York- NY, United States;(9)-, Pfizer Inc, Manila, Philippines;(10)LKS Institute of Health Science- Chinese University of Hong Kong, Institute of Digestive Disease- Department of Medicine and Therapeutics, Hong Kong, China;
P564: A qualitative exploration of acceptability of long-term use of oral nutritional supplement drinks as partial enteral nutrition in adolescent and adult Crohn's DiseaseECCO'22Year: 2022
Authors: Mu, S.(1);Wei, Y.(1);Weekes, E.(2);Keetarut, K.(2);
(1)University College London, Institute for Liver and Digestive Health- UCL Division of Medicine, London, United Kingdom;(2)University College London Hospital, Nutrition and Dietetics, London, United Kingdom;
